GlobeNewswire by notified

Bulletin from the annual general meeting of Hoylu AB (publ) on 10 June 2022

Share

Bulletin from the annual general meeting of Hoylu AB (publ) on 10 June 2022

The annual general meeting of Hoylu AB (publ) (the "Company") was held today, 10 June 2022, the resolutions were passed with required majority in accordance with the board's published proposals. The main resolutions adopted by the meeting are set out below.

Profit appropriation etc.

The annual general Meeting approved the balance sheet and consolidated financial statements as of 31 December 2021 included in the annual report, as well as the income statement and consolidated income statement for the financial year 2021.

The meeting resolved that no dividend shall be paid for the financial year 2021 and that the remaining funds shall be transferred to new account.

The meeting granted all directors during the financial year of 2021 and the CEO discharge from liability for their management of the Company's affairs for the financial year 2021.

Board of directors and auditor

The meeting resolved that the board of directors' fees shall be paid in a total amount of SEK 550,000, of which SEK 250,000 to the chairman of the board and SEK 150,000 each to the other members of the board. No board fee shall be paid to a member who is also an employee of the Company. The meeting also resolved that the auditor's fee shall be paid in accordance with the approved invoice.

The meeting resolved, in accordance with the board's proposal, that the Board shall until the end of the next meeting consist of Johan Lindqvist (re-election), Reidar Fougner (re-election), Fredrik Urbanski (re-election) and Hans Othar Blix (re-election). Johan Lindqvist was re-elected chairman of the board.

The auditing company Deloitte AB was re-elected as the Company's auditor with Henrik Ekström as auditor in charge.

Resolution to amend the terms for outstanding convertible loan

The meeting resolved, in accordance with the board's proposal, to amend the terms of outstanding convertible notes. The amendment relates to the conversion rate for outstanding convertible loans and now amounts to SEK 1.00 per new share.

Resolution on directed convertible bond issue

The meeting resolved, with required majority, in accordance with the shareholder Alden AS proposal, to carry out a directed issue of convertible notes. The resolution is governed by the following terms and conditions.

  1. The right to subscribe for the convertible notes shall vest in Fougner Invest AS (controlled by Reidar Fougner), Trellevika Invest AS (controlled by Reidar Fougner 's wife), Fredrik Fougner (son of Reidar Fougner), TTC Invest AS (controlled by Fredrik Urbanski), Skadi AS (controlled by Hans Othar Blix), Windchange Invest AB (controlled by Johan Lindqvist), Baklid Invest AS (controlled by Truls Baklid) and CeWi Invest AS (controlled by Karl Wiersholm). The reason for deviating from the shareholders’ pre-emption rights is to enable investments in the Company from the board members Reidar Fougner, Fredrik Urbanski, Hans Othar Blix, Johan Lindqvist and members of the Company’s management, Truls Baklid and Karl Wiersholm and to achieve alignment with the Company’s shareholders. Furthermore, the Company can raise capital in a time- and cost-efficient manner through a directed issue.
  2. The nominal amount of the convertible note shall be SEK 1 or integral multiples thereof. The notes carry an annual interest rate of 6 per cent in accordance with the provisions set out in the terms and conditions, Appendix 1A.
  3. The subscription price shall be equal to the nominal amount of the convertible notes.
  4. Subscription shall take place within three (3) days of the date of the resolution to issue the convertible notes. Payment for the subscribed convertible notes shall be made within one (1) week of the time of subscription.
  5. The convertible notes may be converted into shares during the period commencing on the date of registration, at the Swedish Companies Registration Office, of the resolution regarding the issue up to, and including, October 31, 2022, at a conversion price of SEK 1.00.
  6. Any share premium shall be transferred to the unrestricted premium reserve.


Share capital, shares, and dilution

Upon full conversion of the convertible notes (excluding accrued interest) the share capital will increase by an additional amount of approximately SEK 1,236,585 by the issue of 15,000,000 new shares. The dilution for existing shareholders amounts to a maximum of approximately 14,0 per cent.

Resolution to authorize the board to resolve on issue of shares, convertibles and/or warrants

The meeting resolved to authorise the board of directors to resolve on the issue of shares, convertibles and/or warrants.

For more information, please contact:

Truls Baklid, CEO Hoylu + 47 924 38 900 Email: tob@hoylu.com
Karl Wiersholm, CFO Hoylu + 1 425 829 2316 Email: kw@hoylu.com

About Hoylu
Hoylu’s mission is to empower distributed teams to collaborate easily and seamlessly while always staying in sync. Hoylu’s Connected Workspaces™ helps enterprises as well as small and medium companies run projects, programs, and initiatives across time zones and continents with the same level of engagement and clarity as if everyone were working in the same room.
For more information: www.hoylu.com

Ticker symbol: Hoylu
Marketplace: Nasdaq First North Growth Stockholm
Certified Adviser: Mangold Fondkommission AB +46 (0) 8 50 301 550; ca@mangold.se

Publication
The information was submitted for publication, through the agency of the contact persons set out above, at 14:10 CEST on June 10, 2022.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Intervest Offices & Warehouses NV: Press release – Persbericht – Communiqué de presse: openbaarmaking over transparantiekennisgeving19.4.2024 18:00:00 CEST | Press release

Geachte mevrouw, meneer, Gelieve hierbij de links te vinden naar het recente persbericht van Intervest Offices & Warehouses betreffende de openbaarmaking over transparantiekennisgeving. Dear Madam, Sir, Please find hereunder the links to Intervest Offices & Warehouses’ latest press release regarding the publication of a transparency notification. Attachment NL_transparency notification_20240419

23/2024・Trifork Group AG – Shareholders approve all resolutions at the Annual General Meeting 202419.4.2024 17:34:19 CEST | Press release

Company announcement no. 23 / 2024 Schindellegi, Switzerland – 19 April 2024 Shareholders approve all resolutions at the Annual General Meeting 2024 The shareholders of Trifork Group AG (“Trifork“) today approved all resolutions proposed by the Board of Directors at Trifork’s Annual General Meeting 2024 (the “AGM“) which was held at Grabenstrasse 2, 6430 Baar, Switzerland. Dividend payment The shareholders approved the Board of Directors’ proposal to pay a gross dividend of EUR 0.10 per share (equivalent to CHF 0.10 per share) by making a payout from capital contribution reserves to the shareholders. The total gross dividend paid out amounts to CHFk 1,932, equivalent to DKKk 14,809, as calculated per the exchange rate published by the Swiss Federal Customs Administration as of 19 April 2024. The payout from capital contribution reserves is declared in CHF and paid out in DKK. Composition of the Board of Directors The shareholders re-elected Julie Galbo as Chairperson of the Board of Di

Havila Shipping ASA: Årsrapport 202319.4.2024 17:06:25 CEST | Pressemelding

Styret i Havila Shipping ASA har i dag godkjent regnskap og årsrapport for 2023 for konsern og morselskap. Resultatregnskap og balanser er i samsvar med foreløpig regnskap offentliggjort 27. februar 2024. Kontakter: Administrerende direktør Njål Sævik, +47 909 35 722 Finansdirektør Arne Johan Dale, +47 909 87 706 Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 Vedlegg HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no

Havila Shipping ASA : Annual Report 202319.4.2024 17:06:25 CEST | Press release

Today, the Board of Directors of Havila Shipping ASA has approved the financial statements for 2023 for both the Group and the parent company. The accounts are in line with preliminary accounts released on 27 February 2024. Contacts: Chief Executive Officer Njål Sævik, +47 909 35 722 Chief Financial Officer Arne Johan Dale, +47 909 87 706 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons19.4.2024 17:05:00 CEST | Press release

Company announcement – No. 23 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and

HiddenA line styled icon from Orion Icon Library.Eye